月経前症候群(Premenstrual Syndrome)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Premenstrual Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Premenstrual Syndrome – Overview 7
Pipeline Products for Premenstrual Syndrome – Comparative Analysis 8
Premenstrual Syndrome – Therapeutics under Development by Companies 9
Premenstrual Syndrome – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Premenstrual Syndrome – Products under Development by Companies 13
Premenstrual Syndrome – Companies Involved in Therapeutics Development 14
DEKK-TEC, Inc. 14
M et P Pharma AG 15
Pherin Pharmaceuticals, Inc. 16
Umecrine Mood AB 17
Premenstrual Syndrome – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
PH-80PMD – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
progesterone – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
progesterone – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule-1 to Antagonize GABAA Receptor for PMDD – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule-2 to Antagonize GABAA Receptor for PMDD – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
UC-1010 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Premenstrual Syndrome – Recent Pipeline Updates 33
Premenstrual Syndrome – Dormant Projects 34
Premenstrual Syndrome – Product Development Milestones 35
Featured News & Press Releases 35
Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD) 35
Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood’s candidate drug for severe premenstrual symptoms 36
May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38